Live Feeds
● LIVE Updated 1h ago · 6 sources tracked

Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags

Kyverna Therapeutics has released one-year data for its CAR-T therapy, miv-cel, demonstrating drug-free remission and a strong safety profile in patients with generalized Myasthenia Gravis (gMG) and Stiff Person Syndrome (SPS). The company intends to use this long-term durability data to support its FDA submission. Kyverna aims to complete a Biologics License Application (BLA) for the treatment of Stiff Person Syndrome within the current year, positioning itself to potentially secure the first FDA-approved CAR-T therapy for an autoimmune condition.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Miv-cel demonstrated durable, drug-free remission and strong safety in patients with SPS and gMG at one year.
  • ✓ Kyverna is using long-term data to bolster its FDA submission for a rare autoimmune CAR-T therapy.
🛡️ Source Corroboration: 6 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Kyverna released one-year miv-cel data showing durable remission and announced plans for a BLA submission this year.

Live updates

  1. Kyverna reports one-year durability for miv-cel in autoimmune trials

    Kyverna Therapeutics has released one-year data for its CAR-T therapy, miv-cel, demonstrating drug-free remission and a strong safety profile in patients with generalized Myasthenia Gravis (gMG) and Stiff Person Syndrome (SPS). The company intends to use this long-term durability data to support its FDA submission. Kyverna aims to complete a Biologics License Application (BLA) for the treatment of Stiff Person Syndrome within the current year, positioning itself to potentially secure the first FDA-approved CAR-T therapy for an autoimmune condition.

    Why it matters

    CAR-T therapies were originally developed for oncology but are being adapted for autoimmune diseases. Recent safety issues encountered by other companies in the autoimmune CAR-T space make Kyverna's safety and durability data a critical benchmark for the field.

    What is confirmed

    • Miv-cel demonstrated durable, drug-free remission and strong safety in patients with SPS and gMG at one year.
    • Kyverna is using long-term data to bolster its FDA submission for a rare autoimmune CAR-T therapy.

    Still unconfirmed

    • Kyverna is targeting a complete BLA submission for its Stiff Person Syndrome therapy this year.
    • Kyverna is attempting to reset the industry conversation as peers encounter safety snags.

    What to watch next

    • Formal filing of the BLA for Stiff Person Syndrome
    • FDA response to the miv-cel durability data
    • Comparison of miv-cel safety profiles against competing autoimmune CAR-T candidates
    Sources used for this update (6)
    1. Fierce Biotech — Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
    2. Endpoints News — Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
    3. STAT — Kyverna’s cell therapy shows lasting autoimmune benefit
    4. BioSpace — Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
    5. TradingView — KYTX: Miv-cel delivers durable, drug-free remission and strong safety in SPS and gMG at 1 year
    6. genomeweb.com — Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community